{"ts": 1769396843.086627, "content": "Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403 TitlePharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403Cat 0 0 18 Dec 2025 Views 861 Press Release PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors Title PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in P 0 0 21 Aug 2025 Views 2762 News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO TitlePharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025 CategoryNews 0 0 9 Jun 2025 Views 3434 Press Release PharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors TitlePharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced 0 0 19 May 2025 Views 3758 Media Center Subscribe to our website to get latest updates (email@exmaple.com) Subscribe Confirm No Category Show all Press Release News Article PR Video CEO Story Title Author Time uploaded Views Likes 206 Press Release Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403 (\uc8fc)\ud30c\uba65\uc2e0 18 Dec 2025 Views 861 0 205 Press Release Press Release PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors (\uc8fc)\ud30c\uba65\uc2e0 21 Aug 2025 Views 2762 0 204 News Article News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO (\uc8fc)\ud30c\uba65\uc2e0 9 Jun 2025 Views 3434 0 203 Press Release Press Release PharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors (\uc8fc)\ud30c\uba65\uc2e0 19 May 2025 Views 3758 0 202 News Article News Article PharmAbcine and Arontier Partnership for AI-Driven Antibody-Based Drug Development Platform_THE BIO (\uc8fc)\ud30c\uba65\uc2e0 12 Feb 2025 Views 4845 0 201 Press Release Press Release PharmAbcine at JP Morgan Healthcare Conference 2025 (\uc8fc)\ud30c\uba65\uc2e0 10 Jan 2025 Views 4879 0 200 Press Release Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration (\uc8fc)\ud30c\uba65\uc2e0 9 Jan 2025 Views 4199 0 199 Press Release Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration PharmAbcine 16 Oct 2024 Views 4467 0 198 Press Release Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors PharmAbcine 9 Jul 2024 Views 5250 0 197 Press Release Press Release PharmAbcine\u2019s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg PharmAbcine 2 Jul 2024 Views 4828 0 Search New post About Us Executive Committee Board of Directors Scientific Advisory Board History Core Technology Fully Human Antibody Library Antibody Development Antibody Engineering Pipeline Olinvacimab PMC-309 PMC-402 PMC-403 For Investors For Media Careers Recruiting Procedure Careers Guide Job Openings Contact Location Inquiry Partnership Request LinkedIn I Facebook I YouTube 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea HQ +82-42-863-2017 R&D Center +82-42-861-2017 FAX +82-42-863-2080 COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.", "type": "text"}